CARBAMAZEPINE
| Brand name | CARNEXIV |
|---|---|
| Active ingredient | CARBAMAZEPINE |
| Strength | 200MG/20ML (10MG/ML) |
| Dosage form | SOLUTION |
| Route | INTRAVENOUS |
| Modality | Small molecule |
| FDA approval | October 2016 |
| Marketing status | DISCN |
| Patent | Expires | Type |
|---|---|---|
| 11529357 | January 2040 | product |
| 9493582 | February 2033 | product |
| 9750822 | March 2029 | product |
| 7635773 | March 2029 | product |
| 8410077 | March 2029 | product |
| 9629797 | November 2028 | use U-2006 |
| 9770407 | November 2028 | product |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.